{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:06:36Z","timestamp":1793232396191,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjms.2022.01.016","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T22:40:01Z","timestamp":1643841601000},"page":"359-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Early Clinical Experience with Delafloxacin: A Case Series"],"prefix":"10.1016","volume":"363","author":[{"given":"J. Patrik","family":"Hornak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reynoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2022.01.016_bib0001","unstructured":"BAXDELA\u00ae (delafloxacin) [package insert]. Melinta Therapeutics, Inc. 2019."},{"issue":"5","key":"10.1016\/j.amjms.2022.01.016_bib0002","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.amjms.2022.01.016_bib0003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.amjms.2022.01.016_bib0004","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.amjms.2022.01.016_bib0005","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.amjms.2022.01.016_bib0006","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.amjms.2022.01.016_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EI10-0009-2015","article-title":"Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century","volume":"4","author":"Unemo","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.amjms.2022.01.016_bib0008","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"issue":"4","key":"10.1016\/j.amjms.2022.01.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114980","article-title":"Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?","volume":"96","author":"Boyanova","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.amjms.2022.01.016_bib0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jac\/dkz523","article-title":"Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill","volume":"75","author":"Gumbo","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.amjms.2022.01.016_bib0011","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.amjms.2022.01.016_bib0012","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe","volume":"61","author":"Pfaller","year":"2014","journal-title":"Antimicrob Agents Chemother 2017"},{"issue":"3","key":"10.1016\/j.amjms.2022.01.016_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2022.01.016_bib0014","article-title":"DEFINE-CABP Study Group. A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.amjms.2022.01.016_bib0015","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"PROCEED Study Group. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.amjms.2022.01.016_bib0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:40:49Z","timestamp":1757702449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962922000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0002962922000623"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2022.01.016","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Clinical Experience with Delafloxacin: A Case Series","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2022.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}